FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

FASENRA is not indicated for treatment of other eosinophilic conditions.
FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus.

Doctor Thumbnail
Doctor Thumbnail

FASENRA is the only respiratory biologic that combines Q8W maintenance dosing* with at-home or in-office administration options and offers patients the fewest injections per year.1

*Every 8 weeks following the first 3 doses Q4W.1

Talk to your patients about which administration option is most convenient for them.

FASENRA Pen
FASENRA Pen
FASENRA Prefilled Syringe
FASENRA Prefilled Syringe
  • FASENRA is intended for use under the guidance of a healthcare professional. In line with clinical practice, monitoring of patients after administration of biologic agents is recommended1
  • Patients/caregivers may administer with FASENRA Pen after proper training in subcutaneous injection technique and after healthcare professional determines it is appropriate1

Dosing comparisons do not imply comparable efficacy, safety, or FDA-approved indications.

IMPORTANT SAFETY INFORMATION